Completed PHASE3 INTERVENTIONAL 4-arm NCT00144755

R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma

Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma.

Sponsor: Amgen

Conditions Diffuse Large Cell Lymphoma

Interventions Darbepoetin alfa

Updated 6 times since 2017 Last updated: Sep 1, 2015 Started: Dec 31, 2003 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00144755, this PHASE3 trial focuses on Diffuse Large Cell Lymphoma and remains completed. Sponsored by Amgen, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
Lymphoma Study Association

Data source: Lymphoma Study Association

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bordeaux, France , Créteil, France , Ghent, Belgium , Lausanne, Switzerland , Lille, France , Lyon, France , Mont-Godinne, Belgium , Paris, France , Pierre-Bénite, France , Reims, France and 3 more locations